The advent of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) has significantly improved survival outcomes in patients with advanced EGFR‐mutated non‐small cell lung cancer (NSCLC). The gene discussed is EGFR; the disease is lung cancer.